Methods of treating gastrointestinal stromal tumors
The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
1. A method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising:
orally administering to the patient a 150 mg a once daily or twice daily dose of ripretinib, wherein the patient has previously been administered imatinib before administration of the ripretinib, and wherein the treatment provides more than 3 months of progression free survival in patients as determined by mRECIST 1.1, after at least one cycle of 42 days of the daily ripretinib administration.
2. The method of claim 1 , wherein the patient has been previously administered three or more kinase inhibitors, including the imatinib, before administration of the ripretinib.
3. The method of claim 2 , wherein the previously administered three or more kinase inhibitors are each selected from imatinib, sunitinib, regorafenib, lapatinib, gefitinib, erlotinib, vatalanib, and crenolanib.
4. The method of claim 2 , wherein the patient has been previously administered 4 or more lines of therapy.
5. The method of claim 1 , comprising orally administering to the patient a 150 mg a once daily dose of ripretinib, wherein the daily dose is three tablets each comprising 50 mg ripretinib.
6. The method of claim 1 , wherein the treatment provides more than 6 months of progression free survival in patients, as determined by mRECIST 1.1, after at least ten cycles of 42 days of the daily ripretinib administration.